UA92164C2 - Соединения, пригодные для угнетения снк1 - Google Patents

Соединения, пригодные для угнетения снк1

Info

Publication number
UA92164C2
UA92164C2 UAA200710711A UAA200710711A UA92164C2 UA 92164 C2 UA92164 C2 UA 92164C2 UA A200710711 A UAA200710711 A UA A200710711A UA A200710711 A UAA200710711 A UA A200710711A UA 92164 C2 UA92164 C2 UA 92164C2
Authority
UA
Ukraine
Prior art keywords
urea derivatives
derivatives useful
heteroaryl urea
inhibiting chkl
disclosed
Prior art date
Application number
UAA200710711A
Other languages
English (en)
Ukrainian (uk)
Inventor
Френк Диаз
Франсин С. Фароуз
Райан Хоулком
Эдвард А. Кесицкий
Хуа Че Оой
Александер Рудолф
Френк Стейппенбек
Джон Джосеф Годино
Кимба Л. Фишер
Адам Уейд Кук
Original Assignee
Айкос Корпорейшен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айкос Корпорейшен filed Critical Айкос Корпорейшен
Publication of UA92164C2 publication Critical patent/UA92164C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

В заявке раскрыты замещенные мочевины, пригодные в лечении заболеваний и состояний, связанных с повреждением ДНК или нарушением репликации ДНК.Также раскрыты способы изготовления соединений и их применение в качестве терапевтических соединений, например, в лечении рака и других заболеваний, которые отличаются дефектами в репликации ДНК, сегрегацией хромосом или клеточным делением.
UAA200710711A 2005-03-29 2006-03-29 Соединения, пригодные для угнетения снк1 UA92164C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29

Publications (1)

Publication Number Publication Date
UA92164C2 true UA92164C2 (ru) 2010-10-11

Family

ID=36677174

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200710711A UA92164C2 (ru) 2005-03-29 2006-03-29 Соединения, пригодные для угнетения снк1

Country Status (31)

Country Link
US (1) US8093244B2 (ru)
EP (2) EP1869020B1 (ru)
JP (2) JP5117374B2 (ru)
KR (2) KR100912998B1 (ru)
CN (2) CN101151259B (ru)
AR (1) AR056645A1 (ru)
AT (1) ATE490248T1 (ru)
AU (1) AU2006230337B2 (ru)
BR (1) BRPI0609667A2 (ru)
CA (1) CA2602199C (ru)
CR (1) CR9395A (ru)
CY (1) CY1111240T1 (ru)
DE (1) DE602006018590D1 (ru)
DK (1) DK1869020T3 (ru)
EA (1) EA011287B1 (ru)
ES (1) ES2356068T3 (ru)
HR (1) HRP20100678T1 (ru)
IL (1) IL185481A0 (ru)
MA (1) MA29439B1 (ru)
MX (1) MX2007012116A (ru)
NO (1) NO20074944L (ru)
NZ (1) NZ561458A (ru)
PL (1) PL1869020T3 (ru)
PT (1) PT1869020E (ru)
RS (1) RS51616B (ru)
SI (1) SI1869020T1 (ru)
TN (1) TNSN07369A1 (ru)
TW (1) TWI375559B (ru)
UA (1) UA92164C2 (ru)
WO (1) WO2006105262A1 (ru)
ZA (1) ZA200707715B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221367A (en) 1988-08-03 1993-06-22 International Business Machines, Corp. Strained defect-free epitaxial mismatched heterostructures and method of fabrication
MY150649A (en) * 2006-10-20 2014-02-14 Icos Corp Compositions of chk1 inhibitors
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
HRP20220351T1 (hr) 2016-02-04 2022-05-13 Pharmaengine, Inc. 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
US20200108074A1 (en) * 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
JP2001518501A (ja) 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057206A2 (en) 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
AU2001243226A1 (en) 2000-02-25 2001-09-03 The Regents Of The University Of California Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
ATE295354T1 (de) 2000-08-18 2005-05-15 Agouron Pharma Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
CA2434066A1 (en) 2001-01-26 2002-09-12 Pharmacia Italia S.P.A. Chromane derivatives, process for their preparation and their use as antitumor agents
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
DE60229975D1 (de) 2001-10-04 2009-01-02 Smithkline Beecham Corp Nf-kb-inhibitoren
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1501831A1 (en) 2002-04-26 2005-02-02 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
BR0316680A (pt) 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
CA2512683C (en) 2003-01-09 2010-03-16 Pfizer Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
EP1765808A1 (en) * 2004-06-25 2007-03-28 ICOS Corporation Bisarylurea derivatives useful for inhibiting chk1
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Also Published As

Publication number Publication date
JP2008535830A (ja) 2008-09-04
EP2330105A1 (en) 2011-06-08
US8093244B2 (en) 2012-01-10
RS51616B (sr) 2011-08-31
EA011287B1 (ru) 2009-02-27
MX2007012116A (es) 2008-04-08
HK1119670A1 (en) 2009-03-13
TW200722090A (en) 2007-06-16
US20090143357A1 (en) 2009-06-04
TWI375559B (en) 2012-11-01
EA200702094A1 (ru) 2008-02-28
IL185481A0 (en) 2008-01-06
CY1111240T1 (el) 2015-06-11
DE602006018590D1 (de) 2011-01-13
PL1869020T3 (pl) 2011-05-31
CR9395A (es) 2008-03-31
AU2006230337B2 (en) 2011-10-27
JP5117374B2 (ja) 2013-01-16
HRP20100678T1 (hr) 2011-02-28
NZ561458A (en) 2011-03-31
KR20090031459A (ko) 2009-03-25
AU2006230337A1 (en) 2006-10-05
NO20074944L (no) 2007-10-24
CN101151259A (zh) 2008-03-26
CA2602199C (en) 2013-09-10
KR100912998B1 (ko) 2009-08-20
CN101151259B (zh) 2011-06-15
MA29439B1 (fr) 2008-05-02
SI1869020T1 (sl) 2011-02-28
KR20070107178A (ko) 2007-11-06
WO2006105262A1 (en) 2006-10-05
AR056645A1 (es) 2007-10-17
DK1869020T3 (da) 2011-01-24
ATE490248T1 (de) 2010-12-15
BRPI0609667A2 (pt) 2010-04-20
CN102219784A (zh) 2011-10-19
ES2356068T3 (es) 2011-04-04
TNSN07369A1 (en) 2008-12-31
EP1869020B1 (en) 2010-12-01
EP1869020A1 (en) 2007-12-26
ZA200707715B (en) 2009-09-30
PT1869020E (pt) 2010-12-23
CA2602199A1 (en) 2006-10-05
JP2009227682A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
TNSN07369A1 (en) Heteroaryl urea derivatives useful for inhibiting chki
PL364564A1 (en) Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers
WO2009151598A8 (en) Diazacarbazoles and methods of use
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
PL2324008T3 (pl) 3,4-diarylopirazole jako inhibitory kinazy białkowej
WO2009011850A3 (en) Novel therapeutic compounds
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TW200606162A (en) Pyrazolopyridine derivatives
NZ597075A (en) 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
UA103351C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА КАК ИНГИБИТОРЫ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
WO2006021002A3 (en) Compounds useful for inhibiting chk1
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
MX2010013608A (es) Pirroles sustituidos y metodos de uso.
UA99734C2 (ru) Производные азабифениламинобензойной кислоты как ингибиторы dhodh
WO2009027838A3 (en) Kinamycin f for cancer treatment
NZ597948A (en) Combinations for the treatment of diseases involving cell proliferation